216 related articles for article (PubMed ID: 12799025)
21. Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-beta-1a treatment in multiple sclerosis patients.
Mirowska D; Skierski J; Paź A; Koronkiewicz M; Zaborski J; Kruszewska J; Członkowski A; Członkowska A
J Neurol; 2003 Oct; 250(10):1229-36. PubMed ID: 14586608
[TBL] [Abstract][Full Text] [Related]
22. Genomic effects of IFN-beta in multiple sclerosis patients.
Weinstock-Guttman B; Badgett D; Patrick K; Hartrich L; Santos R; Hall D; Baier M; Feichter J; Ramanathan M
J Immunol; 2003 Sep; 171(5):2694-702. PubMed ID: 12928423
[TBL] [Abstract][Full Text] [Related]
23. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
[TBL] [Abstract][Full Text] [Related]
24. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
25. Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.
Mellergård J; Edström M; Jenmalm MC; Dahle C; Vrethem M; Ernerudh J
PLoS One; 2013; 8(12):e81685. PubMed ID: 24312575
[TBL] [Abstract][Full Text] [Related]
26. CD3
Tahrali I; Kucuksezer UC; Akdeniz N; Altintas A; Uygunoglu U; Aktas-Cetin E; Deniz G
Immunol Lett; 2019 Dec; 216():63-69. PubMed ID: 31589897
[TBL] [Abstract][Full Text] [Related]
27. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
28. Preliminary study: treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2+ and decreased levels of IL23R+ CD4+ T - Lymphocytes in multiple sclerosis.
Kress-Bennett JM; Ehrlich GD; Bruno A; Post JC; Hu FZ; Scott TF
BMC Neurol; 2011 Dec; 11():155. PubMed ID: 22182694
[TBL] [Abstract][Full Text] [Related]
29. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis.
Vandenbark AA; Huan J; Agotsch M; La Tocha D; Goelz S; Offner H; Lanker S; Bourdette D
J Neuroimmunol; 2009 Oct; 215(1-2):125-8. PubMed ID: 19758707
[TBL] [Abstract][Full Text] [Related]
30. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays.
Jaber A; Baker M
J Pharm Biomed Anal; 2007 Mar; 43(4):1256-61. PubMed ID: 17118612
[TBL] [Abstract][Full Text] [Related]
31. Lymphocytes in the treatment with interferon beta-1 b.
Pavelek Z; Vyšata O; Klímová B; Andrýs C; Vokurková D; Vališ M
Mult Scler Relat Disord; 2017 Nov; 18():29-32. PubMed ID: 29141817
[TBL] [Abstract][Full Text] [Related]
32. Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta.
Killestein J; Hintzen RQ; Uitdehaag BM; Baars PA; Roos MT; van Lier RA; Polman CH
J Neuroimmunol; 2002 Dec; 133(1-2):217-24. PubMed ID: 12446026
[TBL] [Abstract][Full Text] [Related]
33. Interferon beta 1a.
Pozzilli C; Koudriavtseva T
Baillieres Clin Neurol; 1997 Oct; 6(3):481-93. PubMed ID: 10101585
[TBL] [Abstract][Full Text] [Related]
34. Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells.
Jiang H; Milo R; Swoveland P; Johnson KP; Panitch H; Dhib-Jalbut S
J Neuroimmunol; 1995 Aug; 61(1):17-25. PubMed ID: 7560008
[TBL] [Abstract][Full Text] [Related]
35. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy.
Becher B; Giacomini PS; Pelletier D; McCrea E; Prat A; Antel JP
Ann Neurol; 1999 Feb; 45(2):247-50. PubMed ID: 9989628
[TBL] [Abstract][Full Text] [Related]
36. T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis.
Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
Arch Neurol; 1999 Feb; 56(2):217-22. PubMed ID: 10025427
[TBL] [Abstract][Full Text] [Related]
37. Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis.
Rizzo F; Giacomini E; Mechelli R; Buscarinu MC; Salvetti M; Severa M; Coccia EM
Immunol Cell Biol; 2016 Oct; 94(9):886-894. PubMed ID: 27265253
[TBL] [Abstract][Full Text] [Related]
38. T-cell interleukin-6 receptor binding in interferon-beta-1b-treated multiple sclerosis patients.
Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
Eur J Neurol; 2000 Nov; 7(6):647-53. PubMed ID: 11136350
[TBL] [Abstract][Full Text] [Related]
39. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study.
Marastoni D; Buriani A; Pisani AI; Crescenzo F; Zuco C; Fortinguerra S; Sorrenti V; Marenda B; Romualdi C; Magliozzi R; Monaco S; Calabrese M
Front Immunol; 2019; 10():1666. PubMed ID: 31379857
[No Abstract] [Full Text] [Related]
40. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment.
Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V
J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):123-6. PubMed ID: 12486283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
